These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11777989)

  • 1. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
    Savoldo B; Cubbage ML; Durett AG; Goss J; Huls MH; Liu Z; Teresita L; Gee AP; Ling PD; Brenner MK; Heslop HE; Rooney CM
    J Immunol; 2002 Jan; 168(2):909-18. PubMed ID: 11777989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
    Khanolkar A; Fu Z; Underwood LJ; Bondurant KL; Rochford R; Cannon MJ
    J Immunol; 2003 Mar; 170(6):3187-94. PubMed ID: 12626577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component.
    Misko IS; Sculley TB; Schmidt C; Moss DJ; Soszynski T; Burman K
    Cell Immunol; 1991 Feb; 132(2):295-307. PubMed ID: 1846323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
    Metes D; Storkus W; Zeevi A; Patterson K; Logar A; Rowe D; Nalesnik MA; Fung JJ; Rao AS
    Transplantation; 2000 Nov; 70(10):1507-15. PubMed ID: 11118098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
    Ramadan G
    Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
    Popescu I; Macedo C; Zeevi A; Nellis J; Patterson KR; Logar A; Rowe D; Reyes J; Rao AS; Storkus WJ; Fung JJ; Metes D
    Am J Transplant; 2003 Nov; 3(11):1369-77. PubMed ID: 14525597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen.
    Sun Q; Burton RL; Dai LJ; Britt WJ; Lucas KG
    J Immunol; 2000 Oct; 165(7):4105-11. PubMed ID: 11034422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of variations in levels of Epstein-Barr Virus (EBV) antigen and adaptive immune response during chronic active EBV infection in children.
    Xing Y; Song HM; Wei M; Liu Y; Zhang YH; Gao L
    J Immunotoxicol; 2013; 10(4):387-92. PubMed ID: 23418935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
    Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
    J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children.
    Comoli P; Ginevri F; Maccario R; Frasson C; Valente U; Basso S; Labirio M; Huang GC; Verrina E; Baldanti F; Perfumo F; Locatelli F
    Am J Transplant; 2006 Sep; 6(9):2169-76. PubMed ID: 16796723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood.
    Sun Q; Burton RL; Pollok KE; Emanuel DJ; Lucas KG
    Cell Immunol; 1999 Aug; 195(2):81-8. PubMed ID: 10448007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
    Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
    Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells.
    Lee SP; Chan AT; Cheung ST; Thomas WA; CroomCarter D; Dawson CW; Tsai CH; Leung SF; Johnson PJ; Huang DP
    J Immunol; 2000 Jul; 165(1):573-82. PubMed ID: 10861098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
    Hoffmann T; Russell C; Vindelov L
    APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.